IL143088A0 - A method for the treatment of type 2 diabetes mellitus and conditions associated therewith, and a pharmaceutical composition comprising an insulin sensitiser for use in such a method - Google Patents

A method for the treatment of type 2 diabetes mellitus and conditions associated therewith, and a pharmaceutical composition comprising an insulin sensitiser for use in such a method

Info

Publication number
IL143088A0
IL143088A0 IL14308899A IL14308899A IL143088A0 IL 143088 A0 IL143088 A0 IL 143088A0 IL 14308899 A IL14308899 A IL 14308899A IL 14308899 A IL14308899 A IL 14308899A IL 143088 A0 IL143088 A0 IL 143088A0
Authority
IL
Israel
Prior art keywords
treatment
pharmaceutical composition
type
associated therewith
diabetes mellitus
Prior art date
Application number
IL14308899A
Other languages
English (en)
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10842389&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL143088(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of IL143088A0 publication Critical patent/IL143088A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
IL14308899A 1998-11-12 1999-11-12 A method for the treatment of type 2 diabetes mellitus and conditions associated therewith, and a pharmaceutical composition comprising an insulin sensitiser for use in such a method IL143088A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9824893.3A GB9824893D0 (en) 1998-11-12 1998-11-12 Novel method of treatment
PCT/US1999/026746 WO2000027341A2 (en) 1998-11-12 1999-11-12 Novel method of treatment

Publications (1)

Publication Number Publication Date
IL143088A0 true IL143088A0 (en) 2002-11-10

Family

ID=10842389

Family Applications (1)

Application Number Title Priority Date Filing Date
IL14308899A IL143088A0 (en) 1998-11-12 1999-11-12 A method for the treatment of type 2 diabetes mellitus and conditions associated therewith, and a pharmaceutical composition comprising an insulin sensitiser for use in such a method

Country Status (40)

Country Link
EP (2) EP1759698A1 (cs)
JP (1) JP2003521455A (cs)
KR (2) KR20070048279A (cs)
CN (3) CN1771943A (cs)
AP (2) AP1580A (cs)
AR (2) AR029149A1 (cs)
AT (1) ATE366573T1 (cs)
AU (1) AU768303B2 (cs)
BG (2) BG65577B1 (cs)
BR (1) BR9915284A (cs)
CA (1) CA2350425C (cs)
CO (1) CO5150158A1 (cs)
CY (1) CY1106892T1 (cs)
CZ (1) CZ299801B6 (cs)
DE (1) DE69936533T2 (cs)
DK (1) DK1135128T3 (cs)
DZ (1) DZ2938A1 (cs)
EA (2) EA009192B1 (cs)
ES (1) ES2289833T3 (cs)
GB (1) GB9824893D0 (cs)
HK (1) HK1041202B (cs)
HR (1) HRP20010344B1 (cs)
HU (1) HUP0104262A3 (cs)
IL (1) IL143088A0 (cs)
MA (1) MA26759A1 (cs)
MY (1) MY128347A (cs)
NO (1) NO328391B1 (cs)
NZ (1) NZ527132A (cs)
OA (1) OA12193A (cs)
PE (1) PE20001239A1 (cs)
PL (1) PL349421A1 (cs)
PT (1) PT1135128E (cs)
RS (1) RS50130B (cs)
SK (1) SK286357B6 (cs)
TR (1) TR200101348T2 (cs)
TW (1) TWI234456B (cs)
UA (1) UA79730C2 (cs)
UY (2) UY25797A1 (cs)
WO (1) WO2000027341A2 (cs)
ZA (1) ZA200103793B (cs)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY125516A (en) 1999-11-16 2006-08-30 Smithkline Beecham Plc Novel composition based on thiazolidinedione and metformin and use
AU2002367154A1 (en) * 2001-12-21 2003-07-15 Smithkline Beecham Corporation Dosing regimen for ppar-gamma activators
WO2012074375A1 (en) * 2010-12-01 2012-06-07 N.V. Nutricia Prevention or treatment of overweight and obesity in type 2 diabetic patients

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5522636A (en) * 1978-08-04 1980-02-18 Takeda Chem Ind Ltd Thiazoliding derivative
JPS5697277A (en) * 1980-01-07 1981-08-05 Takeda Chem Ind Ltd Thiazolidine derivative
JPS6051189A (ja) * 1983-08-30 1985-03-22 Sankyo Co Ltd チアゾリジン誘導体およびその製造法
US4582839A (en) * 1984-03-21 1986-04-15 Takeda Chemical Industries, Ltd. 2,4-thiazolidinediones
CN1003445B (zh) * 1984-10-03 1989-03-01 武田药品工业株式会社 噻唑烷二酮衍生物，其制备方法和用途
JPH06779B2 (ja) * 1985-06-10 1994-01-05 武田薬品工業株式会社 チアゾリジオン誘導体およびそれを含んでなる医薬組成物
US4812570A (en) * 1986-07-24 1989-03-14 Takeda Chemical Industries, Ltd. Method for producing thiazolidinedione derivatives
ATE186724T1 (de) * 1987-09-04 1999-12-15 Beecham Group Plc Substituierte thiazolidindionderivate
US4791125A (en) * 1987-12-02 1988-12-13 Pfizer Inc. Thiazolidinediones as hypoglycemic and anti-atherosclerosis agents
MX15171A (es) * 1988-03-08 1993-05-01 Pfizer Derivados de tiazolidinodiona hipoglicemicos
US5061717A (en) * 1988-03-08 1991-10-29 Pfizer Inc. Thiazolidinedione hypoglycemic agents
GB8919417D0 (en) * 1989-08-25 1989-10-11 Beecham Group Plc Novel compounds
WO1991007107A1 (en) * 1989-11-13 1991-05-30 Pfizer Inc. Oxazolidinedione hypoglycemic agents
JPH0469331A (ja) * 1990-07-10 1992-03-04 Asahi Chem Ind Co Ltd 徐放性エマルジョン製剤
JP2572673B2 (ja) * 1990-07-25 1997-01-16 エスエス製薬株式会社 徐放性錠剤
JPH04210683A (ja) * 1990-12-06 1992-07-31 Terumo Corp チアゾリジン−２，４−ジオン誘導体およびこれを含有する糖尿病合併症治療薬
US5183823A (en) * 1991-04-11 1993-02-02 Takeda Chemical Industries, Ltd. Pyridine n-oxide compounds which are useful as hypoglycemic and hypolipidemic agents
FR2680512B1 (fr) * 1991-08-20 1995-01-20 Adir Nouveaux derives de 2,4-thiazolidinedione, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
DE69219136T2 (de) * 1991-08-26 1997-08-28 Pharmacia & Upjohn Co., Kalamazoo, Mich. Flüssiges nahrungsmittel, das 3-guanidinopropionsäure enthält
GB9218830D0 (en) * 1992-09-05 1992-10-21 Smithkline Beecham Plc Novel compounds
US5478853A (en) * 1992-10-12 1995-12-26 Adir Et Compagnie Thazolidinedione compounds
US5506245A (en) * 1992-10-12 1996-04-09 Adir Et Compagnie Thiazolidinedione compounds
CA2115587A1 (en) * 1993-02-18 1994-08-19 Hayato Kihara Styrene copolymers, polystyrene compositions, processes for producing styrene copolymers, and injection-molded articles
DE4317320A1 (de) * 1993-05-25 1994-12-01 Boehringer Mannheim Gmbh Neue Thiazolidindione und diese enthaltende Arzneimittel
FI961213L (fi) * 1993-09-15 1996-05-14 Sankyo Co Tiatsolidinidionien käyttö insuliinista riippumattoman sokeritaudin syntymisen ehkäisemiseksi tai viivyttämiseksi
US5457109A (en) * 1993-09-15 1995-10-10 Warner-Lambert Company Use of thiazolidinedione derivatives and related antihyperglycemic agents in the treatment of disease states at risk for progressing to noninsulin-dependent diabetes mellitus
US5902726A (en) * 1994-12-23 1999-05-11 Glaxo Wellcome Inc. Activators of the nuclear orphan receptor peroxisome proliferator-activated receptor gamma
US5708012A (en) * 1995-04-28 1998-01-13 Sankyo Company, Limited Use of thiazolidinedione derivatives and related antihyperglycemic agents in the treatment of insulin resistant subjects with normal glucose tolerance in order to prevent or delay the onset of noninsulin-dependent mellitus
US6011049A (en) * 1997-02-19 2000-01-04 Warner-Lambert Company Combinations for diabetes
US5859037A (en) * 1997-02-19 1999-01-12 Warner-Lambert Company Sulfonylurea-glitazone combinations for diabetes

Also Published As

Publication number Publication date
AR029149A1 (es) 2003-06-18
ZA200103793B (en) 2002-06-05
RS50130B (sr) 2009-03-25
EP1135128A4 (en) 2003-07-16
EA200100539A1 (ru) 2001-12-24
PL349421A1 (en) 2002-07-29
AP2005003432A0 (en) 2005-12-31
UY25801A1 (es) 2000-08-21
HRP20010344B1 (en) 2008-02-29
CY1106892T1 (el) 2012-01-25
EP1759698A1 (en) 2007-03-07
HK1041202B (en) 2007-10-05
CZ20011656A3 (cs) 2002-06-12
KR20010080440A (ko) 2001-08-22
AU1719600A (en) 2000-05-29
TWI234456B (en) 2005-06-21
BG110061A (bg) 2008-12-30
PT1135128E (pt) 2007-10-12
EA009192B1 (ru) 2007-12-28
NZ527132A (en) 2005-01-28
SK286357B6 (sk) 2008-08-05
CN1235586C (zh) 2006-01-11
BG65577B1 (bg) 2009-01-30
PE20001239A1 (es) 2000-12-24
CN1354661A (zh) 2002-06-19
CN101244062A (zh) 2008-08-20
ATE366573T1 (de) 2007-08-15
DE69936533D1 (de) 2007-08-23
HUP0104262A2 (en) 2002-08-28
DE69936533T2 (de) 2008-03-13
EA200700968A1 (ru) 2008-06-30
HUP0104262A3 (en) 2003-06-30
YU37401A (sh) 2005-07-19
TR200101348T2 (tr) 2002-02-21
SK6422001A3 (en) 2001-12-03
CZ299801B6 (cs) 2008-11-26
HK1041202A1 (en) 2002-07-05
BG105569A (en) 2002-01-31
UY25797A1 (es) 2000-12-29
HRP20010344A2 (en) 2002-06-30
JP2003521455A (ja) 2003-07-15
CA2350425C (en) 2009-06-02
AU768303B2 (en) 2003-12-04
EP1135128A2 (en) 2001-09-26
NO20012301D0 (no) 2001-05-10
CA2350425A1 (en) 2000-05-18
DZ2938A1 (fr) 2004-03-15
NO20012301L (no) 2001-07-09
CO5150158A1 (es) 2002-04-29
EP1135128B1 (en) 2007-07-11
NO328391B1 (no) 2010-02-08
DK1135128T3 (da) 2007-11-05
MY128347A (en) 2007-01-31
WO2000027341A2 (en) 2000-05-18
WO2000027341A3 (en) 2000-09-08
KR20070048279A (ko) 2007-05-08
BR9915284A (pt) 2002-02-13
CN1771943A (zh) 2006-05-17
ES2289833T3 (es) 2008-02-01
OA12193A (en) 2006-05-09
AP1580A (en) 2006-02-24
MA26759A1 (fr) 2004-12-20
UA79730C2 (en) 2007-07-25
AR029317A1 (es) 2003-06-25
GB9824893D0 (en) 1999-01-06

Similar Documents

Publication Publication Date Title
IL173650A0 (en) A pharmaceutical composition for treating diabetes mellitus comprising an insulin sensitizer and a biguanide antihyperglycaemic agent
NL300432I2 (en) Pharmaceutical composition comprising pioglitazoneand glimepiride for use in treatment of diabetes.
ZA99104B (en) Method for administering ASPB28-human insulin.
HUP0200556A3 (en) Medicament for treating diabetes
ZA975866B (en) Novel heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases.
AU4072799A (en) 2,3,5-substituted biphenyls useful in the treatment of insulin resistance and hyperglycemia
ZA989744B (en) Method for administering acylated insulin.
EE04175B1 (et) Meetod topiramaadi farmatseutilise kompositsioonivalmistamiseks, farmatseutiline kompositsioon ning topiramaadi kasutamine diabeedi raviks ette nähtud ravimi valmistamiseks
IL148870A (en) 2'-substituted 1,1'-biphenyl - 2 - carbonamides, method for the production thereof, use thereof as medicament and pharmaceutical preparations containing said compounds
EP0688570A3 (de) Insulinspritze
AU2003251933A8 (en) Method for increasing insulin sensitivity and for treating and preventing type 2 diabetes
HRP990080B1 (en) Plant mixture and a medical preparation for the treatment of diabetes mellitus, type ii, obtained therefrom
IL125820A0 (en) Therapeutic agent for diabetes and a pharmaceutical composition containing the same
CA2296653A1 (en) Treatment of diabetes with thiazolidinedione, insulin secretagogue and biguanide
GB2363714B (en) Herbal composition and medicament against diabetes mellitus type II manufactured thereof
BG104059A (en) Diabetes treatment with rosiglytazone and insulin
EP0683668A4 (en) PREPARATIONS AND METHODS FOR TRANSDERMAL DRUG ADMINISTRATION.
EP1539153A4 (en) THERAPEUTIC TREATMENT OF METABOLIC SYNDROME AND FOR DIABETES TYPE 2
HUP0003626A3 (en) Pharmaceutical composition for treatment of diabetes with thiazolidinedione, insulin secretagogue and alpha glucocidase inhibitor
IL143088A0 (en) A method for the treatment of type 2 diabetes mellitus and conditions associated therewith, and a pharmaceutical composition comprising an insulin sensitiser for use in such a method
WO1999053064A3 (en) Methods of delivering glp-1
CA2294385A1 (en) Treatment of diabetes with thiazolidinedione and sulphonylurea
CZ20011655A3 (cs) Léčivo pro léčení diabetes mellitus a stavů s ním spojených a farmaceutický prostředek obsahující beta -agonistu a daląí antidiabetické činidlo
MY138246A (en) Treatment of diabetes with thiazolidione and sulphonylurea.
HU9700989D0 (en) Ortho-substituted benzoyl-guanidines, process for producing them, their use as medicament and diagnosticment, pharmaceutical compositions containing them